Skip to main content

Table 2 Performance of the AP4 relapse test in validation cohorts

From: Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer

Cohort

% AP4-

5 year survival

(95% CI)

10 year survival

(95% CI)

Hazard ratio

(95% CI)

Logrank

p-value

OXFD+

38%

0.96 (0.90 – 1.00)

0.93 (0.86 – 1.00)

6.73 (2.02 – 22.4)

3 × 10-4

MZ+

47%

0.92 (0.86 – 0.98)

0.85 (0.75 – 0.95)

2.23 (1.02 – 4.87)

0.039

GUYT+

31%

0.96 (0.89 – 1.00)

0.88 (0.76 – 1.00)

3.09 (0.90 – 10.5)

0.058

GUYT2+

36%

No metastases in AP4-

   

TOTAL

40%

0.95 (0.93 – 0.98)

0.89 (0.85 – 0.93)

3.76 (2.16 – 6.56)

5.14 × 10-7

  1. The 5 and 10 year metastsis-free survival probabilities for the AP4- groups in the validation cohorts, the hazard ratio for AP4- to AP4+, and the logrank p-value.